Questionnaire (SGRQ) total score and % responders ([4 unit improvement)], % of patients with C1 exacerbations, adverse events (AE), serious adverse events (SAE), hospitalization and mortality, all at 24 weeks.
In the absence of head-to-head trials between aclidinium/formoterol and tiotropium, a Bayesian indirect treatment comparison (ITC) was used with placebo as common control. Results: Regarding bronchodilation, aclidinium/formoterol was found to be more efficacious than tiotropium at peak FEV 1 
INTRODUCTION

Chronic obstructive pulmonary disease (COPD)
is a disorder characterized by the progressive development of airway obstruction, which manifests as an accelerated decline in lung function, with symptoms such as breathlessness on physical exertion, deteriorating health status and exacerbations [1] . Currently COPD is the fourth leading cause of death globally [2] , a major cause of morbidity and mortality, projected to become the world's third leading cause of mortality by 2020 [3] .
Characterized by progressive airflow limitation, COPD also has a major economic impact [4] .
According to the COPD Guidelines from 2011, which were updated in 2015, it is recommended to combine two long-acting bronchodilators in moderate-to-severe COPD patient groups [5] . The combination of two bronchodilators with different mechanisms of action, such as long-acting muscarinic antagonists (LAMAs) and long-acting b2-agonists (LABAs), are a successful treatment option for patients with COPD. Compared to single bronchodilators, the combination of LAMAs and LABAs demonstrates significant improvements in lung function without increasing the risk for adverse events [5] [6] [7] [8] .
The use of fixed-dose combinations (FDCs) of LABAs and LAMAs provide the opportunity to improve the accessibility and conformity compared to separate inhalers. Also, the dose of each substance used in the combination can be enhanced. An objection related to the development of an FDC is the arrangement of improved bronchodilation over monotherapy segments, while adjusting the associated adverse effects with efficacy [9] . The safety and efficacy profiles of both LAMAs and LABAs are well accepted. However, it is important to recognize both the similarities and differences in both efficacy and safety, when combining two substances. Furthermore, in the aclidinium/formoterol group, the frequency of exacerbations is also reduced compared to placebo [6] .
Tiotropium 18 lg is a once-daily treatment and has been the first and most widely prescribed LAMA for COPD, considered as the standard of care in many countries [12] . Based on the outcomes of the AUGMENT and ACLIFORM studies, it is expected that an FDC of aclidinium/formoterol will be more efficient on key COPD outcomes, compared to LAMA 
Study Selection Process
The relevance of each citation identified was assessed according to predefined abstract selection criteria (Supplementary Table S2 ).
First, titles and abstracts were screened for eligibility, and then full texts of the selected articles were assessed by one researcher and checked against the original study by another.
Those that met the inclusion criteria were included for data extraction. 
Data Abstraction and Quality Assessment
For the studies identified that met the inclusion criteria, details were extracted on population characteristics, interventions, outcomes and the study design of interest at 24 weeks The validity of each trial used in the ITC was assessed using the National Institute of Health and Clinical Excellence (NICE) checklist. The results of this assessment were not explicitly used in the ITC, but serve as additional information to determine the quality of the evidence base when interpreting the results Table S3 ).
(Supplementary
Data Synthesis: Indirect Treatment Comparison
The existence of a connection between the treatments of interest via a common control (placebo), as well as the study design and patient characteristics of the identified studies, was used to assess the feasibility of a valid ITC [13] . Subsequently, the identified evidence was used to perform an ITC within a Bayesian framework to simultaneously synthesize the results of the included studies and obtain relative treatment effects [14, 15] . A linear model with normal likelihood distribution was used for continuous outcomes, and a Poisson likelihood with a log link for the dichotomous outcomes [16] . Flat (non-informative) prior distributions, normal with zero mean and variance of 10,000, were assumed for the relative treatment effects of all outcomes. A uniform distribution with range 0-5 was used as the prior of the between-study standard deviation.
For each outcome, a fixed and a random effects model was evaluated. The goodness of fit of each model to the data was assessed using the deviance information criterion [17] . The posterior densities were estimated using the software was used for the analyses and the models were based on those defined by Dias et al. [18] . The posterior distributions were summarized with the median to reflect the most likely value of the estimate, and the 2.5th and 97.5th percentile to capture the 95% credible interval (CrI). For each end point, the probability that each treatment was better than a certain comparator was established.
RESULTS
Search and Selection Results
After searching, a total of 2401 abstracts from the databases and 88 clinical trials from ClinicalTrials.gov were identified (Fig. 1) . Following the abstracts and full-text publication screening stages, 17 full-text publications [8, 12, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] were identified and 3 clinical study reports [34] [35] [36] were provided by AstraZeneca. In total, the evidence base comprised 15 different studies; 13 studies [8, 12, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] 36 ] compared tiotropium 18 lg to placebo (14,697 patients) and two studies [34, 35] compared aclidinium/formoterol 400/12 lg to placebo (1246 patients).
Study Characteristics
An overview of the study characteristics is presented in Table S3 ). In general, the method of randomization and concealment of treatment allocation was well reported.
Patient Characteristics
An overview of the main patient characteristics is provided in Table 2 . The enrolled patients were adults with a COPD diagnosis. The studies included a predominantly male population, ranging from 50% [35] to 99% [24] , while in three studies [21, 24 , 31] more than 80% of the included patients were male in both arms. The patients' average age across all the studies was similar (range 63-68 years). Overall, spirometry measures were fairly consistent at baseline. 
Indirect Treatment Comparison
Despite some differences identified across the studies in terms of study design and patient characteristics, the 15 RCTs (reported in 20 publications) are considered to be broadly comparable and the ITC was feasible [13] . The diagram of the trials included in the ITC is shown in Fig. 2 .
Efficacy Outcomes
Individual study results for efficacy outcomes are presented in Supplementary Table S5, where data not reported but estimated are denoted by an asterisk. The results of the ITC analysis are presented in Table 3 . Regarding lung function, for both outcomes considered in this study, i.e., peak and trough FEV 1 , aclidinium/formoterol 400/12 lg appeared to be more efficacious compared to tiotropium 18 lg at 24 weeks. Table 1 ). Furthermore, the percentage of patients with at least one exacerbation in the placebo arm is almost 3.5 times higher in Donohue et al. 2002 and 2003 [26, 27] (45.8%) than in M/40464/30R (13.4%) [34] , suggesting differences in COPD severity, in exacerbation-related study inclusion criteria or in the way the exacerbations were defined/ reported. For these reasons, the results of the ITC shall be interpreted with caution.
Safety Outcomes
For the safety outcomes, the individual study results are presented as: number of patients with an event (n); number of patients included in the analysis (N); and proportion of patients with an event per treatment arm (Supplementary Table S6 In addition, bias could be introduced due to the imbalances in potential treatment effect modifiers (e.g., FEV 1 predicted at baseline) and differences in the background medications. Due to the lack of access to individual patient data and the low number of studies (especially for aclidinium/formoterol), it was not feasible to further explore these differences.
Furthermore, it is considered complicated to include safety in indirect comparisons, since this is not a straightforward approach. However, we decided to include safety next to efficacy outcomes, since a benefit-risk assessment will add important data about the intervention.
CONCLUSION
The results of this analysis suggest that aclidinium/formoterol is more efficacious with a similar safety profile compared to tiotropium.
ACKNOWLEDGMENTS
This study was conducted by Mapi on behalf of AstraZeneca, who funded the study and the writing of this manuscript. Article processing charges for this study were also funded by 
